Inflammation Clinical Trial
— ANTIOX001Official title:
Evaluation of the Antioxidant Effect of a Mixture of Ozonated Vegetable Oil and Vitamin Complex (Vitamin K2 and Vitamin B9) in Moderately Active Subjects With "Physical Activity Level" (LAF: 1.70-1.99): Pilot Study
Verified date | October 2022 |
Source | S&R Farmaceutici spa |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this pilot study is to evaluate the antioxidant effect of a nutraceutical formulation based on vegetable oil and vitamin complex (vitamin K2 and vitamin B9) in subjects with the same level of physical activity (LAF 1.70-1.99, normally active or moderately active).
Status | Completed |
Enrollment | 20 |
Est. completion date | March 24, 2023 |
Est. primary completion date | February 15, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Subjects of both sexes; - Aged between 18 and 60 years, naïve to taking antioxidant supplements; - Absent of chronic diseases and current therapies; - willing and able to understand and sign an informed consent; - willing to follow a dietary pattern developed according to the LARN (Reference Intake Levels of Nutrients and Energy for the Italian Population) guidelines that establish reference intake levels for Average Energy Requirement (AR) and Macronutrients (Carbohydrates, Lipids and Protein) for the Italian adult population [LARN Tables*]; - Hematobiochemical examinations in normal range: blood count, lipid status, renal and liver function, inflammatory status (Tnfa, C-reactive protein, ESR), glycemic profile (Fasting blood glucose, HbA1C, insulinemia, Homa Index); - BMI in the normal range (18-24.99); - Physical activity level LAF 1.70-1.99 (normally active or moderately active) Exclusion Criteria: - Chronic diseases (chronic renal failure, chronic hepatocellular failure, autoimmune diseases, chronic inflammatory bowel disease, diabetes mellitus, end-stage neoplasms, symptomatic chronic ischemic heart disease) - Severe hypertension; - High-grade hypercholesterolemia; - Age < 18 years; - Poor compliance; - Intake of dietary supplements containing antioxidants; - Untreated hypothyroidism; - Pregnant and lactating women; - Underweight subjects (BMI =18.49); - Overweight subjects (25= BMI =30); - Subjects with obesity (BMI =30); - Subjects with different levels of physical activity: very active (LAF 2.00-2.40) and sedentary (LAF 1.40-1.69). |
Country | Name | City | State |
---|---|---|---|
Italy | Crabion srl | Corciano | Perugia |
Lead Sponsor | Collaborator |
---|---|
S&R Farmaceutici spa |
Italy,
Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR Jr, Tudor-Locke C, Greer JL, Vezina J, Whitt-Glover MC, Leon AS. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011 Aug;43(8):1575-81. doi: 10.1249/MSS.0b013e31821ece12. — View Citation
Askari G, Ghiasvand R, Feizi A, Ghanadian SM, Karimian J. The effect of quercetin supplementation on selected markers of inflammation and oxidative stress. J Res Med Sci. 2012 Jul;17(7):637-41. — View Citation
Barbieri E, Sestili P. Reactive oxygen species in skeletal muscle signaling. J Signal Transduct. 2012;2012:982794. doi: 10.1155/2012/982794. Epub 2011 Dec 5. — View Citation
Buonocore D, Verri M, Giolitto A, Doria E, Ghitti M, Dossena M. Effect of 8-week n-3 fatty-acid supplementation on oxidative stress and inflammation in middle- and long-distance running athletes: a pilot study. J Int Soc Sports Nutr. 2020 Nov 11;17(1):55. doi: 10.1186/s12970-020-00391-4. — View Citation
Dhavamani S, Poorna Chandra Rao Y, Lokesh BR. Total antioxidant activity of selected vegetable oils and their influence on total antioxidant values in vivo: a photochemiluminescence based analysis. Food Chem. 2014 Dec 1;164:551-5. doi: 10.1016/j.foodchem.2014.05.064. Epub 2014 May 22. — View Citation
El-Hamidi M. Zaher FA. Production of vegetable oils in the world and in Egypt: An overview. Bull Natl Res Cent. 2018, 42, 1-9. doi: 10.1186/s42269-018-0019-0.
Kim JG, Yousef AE, Dave S. Application of ozone for enhancing the microbiological safety and quality of foods: a review. J Food Prot. 1999 Sep;62(9):1071-87. doi: 10.4315/0362-028x-62.9.1071. — View Citation
Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, Gargiulo G, Testa G, Cacciatore F, Bonaduce D, Abete P. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018 Apr 26;13:757-772. doi: 10.2147/CIA.S158513. eCollection 2018. — View Citation
Mironczuk-Chodakowska I, Witkowska AM, Zujko ME. Endogenous non-enzymatic antioxidants in the human body. Adv Med Sci. 2018 Mar;63(1):68-78. doi: 10.1016/j.advms.2017.05.005. Epub 2017 Aug 17. — View Citation
Misurcova L, Ambrozova J, Samek D. Seaweed lipids as nutraceuticals. Adv Food Nutr Res. 2011;64:339-55. doi: 10.1016/B978-0-12-387669-0.00027-2. — View Citation
Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006 Oct 18;296(15):1885-99. doi: 10.1001/jama.296.15.1885. Erratum In: JAMA. 2007 Feb 14;297(6):590. — View Citation
Orsavova J, Misurcova L, Ambrozova JV, Vicha R, Mlcek J. Fatty Acids Composition of Vegetable Oils and Its Contribution to Dietary Energy Intake and Dependence of Cardiovascular Mortality on Dietary Intake of Fatty Acids. Int J Mol Sci. 2015 Jun 5;16(6):12871-90. doi: 10.3390/ijms160612871. — View Citation
Petraru A, Ursachi F, Amariei S. Nutritional Characteristics Assessment of Sunflower Seeds, Oil and Cake. Perspective of Using Sunflower Oilcakes as a Functional Ingredient. Plants (Basel). 2021 Nov 17;10(11):2487. doi: 10.3390/plants10112487. — View Citation
Powers SK, Deminice R, Ozdemir M, Yoshihara T, Bomkamp MP, Hyatt H. Exercise-induced oxidative stress: Friend or foe? J Sport Health Sci. 2020 Sep;9(5):415-425. doi: 10.1016/j.jshs.2020.04.001. Epub 2020 May 4. — View Citation
Powers SK, Ji LL, Kavazis AN, Jackson MJ. Reactive oxygen species: impact on skeletal muscle. Compr Physiol. 2011 Apr;1(2):941-69. doi: 10.1002/cphy.c100054. — View Citation
Reid MB. Invited Review: redox modulation of skeletal muscle contraction: what we know and what we don't. J Appl Physiol (1985). 2001 Feb;90(2):724-31. doi: 10.1152/jappl.2001.90.2.724. — View Citation
Romero AC. et al. 2013, 'The Exogenous Antioxidants', in J. A. Morales-González (ed.), oxidative Stress and Chronic Degenerative Diseases - A Role for Antioxidants, IntechOpen, London. doi: 10.5772/52490.
Romeu M, Aranda N, Giralt M, Ribot B, Nogues MR, Arija V. Diet, iron biomarkers and oxidative stress in a representative sample of Mediterranean population. Nutr J. 2013 Jul 16;12:102. doi: 10.1186/1475-2891-12-102. — View Citation
Sakellariou GK, Jackson MJ, Vasilaki A. Redefining the major contributors to superoxide production in contracting skeletal muscle. The role of NAD(P)H oxidases. Free Radic Res. 2014 Jan;48(1):12-29. doi: 10.3109/10715762.2013.830718. Epub 2013 Oct 7. — View Citation
Simioni C, Zauli G, Martelli AM, Vitale M, Sacchetti G, Gonelli A, Neri LM. Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging. Oncotarget. 2018 Mar 30;9(24):17181-17198. doi: 10.18632/oncotarget.24729. eCollection 2018 Mar 30. — View Citation
Tan BL, Norhaizan ME. Effect of High-Fat Diets on Oxidative Stress, Cellular Inflammatory Response and Cognitive Function. Nutrients. 2019 Oct 25;11(11):2579. doi: 10.3390/nu11112579. — View Citation
Yildirim E, Cinar M, Yalcinkaya I, Ekici H, Atmaca N, Guncum E. Effect of cocoa butter and sunflower oil supplementation on performance, immunoglobulin, and antioxidant vitamin status of rats. Biomed Res Int. 2014;2014:606575. doi: 10.1155/2014/606575. Epub 2014 Jul 16. — View Citation
* Note: There are 22 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of hematic oxidative stress by quantifying ROS (CARR U) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up | baseline value before crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying ROS (CARR U) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 15 days of treatment before crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying ROS (CARR U) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 30 days of treatment before crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying ROS (CARR U) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 60 days of treatment before crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying ROS (CARR U) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up | baseline after crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying ROS (CARR U) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 15 days of treatment after crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying ROS (CARR U) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 30 days of treatment after crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying ROS (CARR U) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying reactive oxygen metabolites (ROS) using CARR U as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 60 days of treatment after crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up | Baseline before crossover | |
Primary | Evaluation of hematic oxidative stress by biological antioxidant potential (umol/l) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 15 days of treatment before crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 30 days of treatment before crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 60 days of treatment before crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up | baseline after crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 15 days of treatment after crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 30 days of treatment after crossover | |
Primary | Evaluation of hematic oxidative stress by quantifying biological antioxidant potential (umol/l) | Evaluation of the ability of the dietary supplement to modulate oxidative stress over time by quantifying biological antioxidant potential using umol/l as units of measure comparing with the placebo-treated group at each follow-up | evaluation after 60 days of treatment after crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying C-Reactive Protein (CRP) | Evaluation of the modulation of inflammatory parameters by C-Reactive Protein (CRP) using mg/dl as unit of measure | baseline value before crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying C-Reactive Protein (CRP) | Evaluation of the modulation of inflammatory parameters by C-Reactive Protein (CRP) using mg/dl as unit of measure | evaluation after 60 days of treatment before crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying C-Reactive Protein (CRP) | Evaluation of the modulation of inflammatory parameters by C-Reactive Protein (CRP) using mg/dl as unit of measure | baseline after crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying C-Reactive Protein (CRP) | Evaluation of the modulation of inflammatory parameters by C-Reactive Protein (CRP) using mg/dl as unit of measure | evaluation after 60 days of treatment after crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Erythrocyte Sedimentation Rate (ESR) | Evaluation of the modulation of inflammatory parameters by measuring Erythrocyte Sedimentation Rate (ESR) using mm/h as unit of measure | baseline value before crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Erythrocyte Sedimentation Rate (ESR) | Evaluation of the modulation of inflammatory parameters by measuring Erythrocyte Sedimentation Rate (ESR) using mm/h as unit of measure | evaluation after 60 days of treatment before the crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Erythrocyte Sedimentation Rate (ESR) | Evaluation of the modulation of inflammatory parameters by measuring Erythrocyte Sedimentation Rate (ESR) using mm/h as unit of measure | baseline after crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Erythrocyte Sedimentation Rate (ESR) | Evaluation of the modulation of inflammatory parameters by measuring Erythrocyte Sedimentation Rate (ESR) using mm/h as unit of measure | evaluation after 60 days of treatment after crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfa) | Evaluation of the modulation of inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfa) using pg/mL as unit of measure | baseline value before crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfa) | Evaluation of the modulation of inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfa) using pg/mL as unit of measure | evaluation after 60 days of treatment before crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfa) | Evaluation of the modulation of inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfa) using pg/mL as unit of measure | baseline after crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfa) | Evaluation of the modulation of inflammatory parameters by quantifying Tumor Necrosis Factor (Tnfa) using pg/mL as unit of measure | evaluation after 60 days of treatment after crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Cortisol level | Evaluation of the modulation of inflammatory parameters by measuring Cortisol level using µg/dl as unit of measure | baseline value before crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Cortisol level | Evaluation of the modulation of inflammatory parameters by measuring Cortisol level using µg/dl as unit of measure | evaluation after 60 days of treatment before crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Cortisol level | Evaluation of the modulation of inflammatory parameters by measuring Cortisol level using µg/dl as unit of measure | baseline value after crossover | |
Secondary | Assessment of hematic inflammatory parameters by quantifying Cortisol level | Evaluation of the modulation of inflammatory parameters by measuring Cortisol level using µg/dl as unit of measure | evaluation after 60 days of treatment after crossover |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03995979 -
Inflammation and Protein Restriction
|
N/A | |
Completed |
NCT03255187 -
Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT03577223 -
Egg Effects on the Immunomodulatory Properties of HDL
|
N/A | |
Completed |
NCT04383561 -
Relationship Between LRG and Periodontal Disease
|
N/A | |
Active, not recruiting |
NCT03622632 -
Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
|
||
Completed |
NCT06216015 -
Exercise Training and Kidney Transplantation
|
N/A | |
Completed |
NCT04856748 -
Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
|
||
Completed |
NCT05529693 -
Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population
|
N/A | |
Recruiting |
NCT05415397 -
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
|
Phase 3 | |
Recruiting |
NCT05670301 -
Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases
|
N/A | |
Recruiting |
NCT04543877 -
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
|
Early Phase 1 | |
Recruiting |
NCT05775731 -
Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
|
||
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Completed |
NCT03429920 -
Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors
|
N/A | |
Completed |
NCT06065241 -
Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals.
|
N/A | |
Completed |
NCT05864352 -
The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
|
||
Completed |
NCT03318731 -
Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males
|
N/A | |
Not yet recruiting |
NCT06134076 -
Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota
|
N/A | |
Not yet recruiting |
NCT06159543 -
The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes
|
N/A |